Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of -1166.83x is 13420% below its 4-year average of -8.63x, near the low end of its 4-year range (-1166.83x–18.94x).
As of the fiscal period ended Sunday, December 31, 2023. 280.36% below its 12-month average of -306.77x.
Reported quarterly interest coverage; no daily interpolation. Q4 FY2023 (2023-12-31): -1166.83x.
INTEREST COVERAGE RATIO
-1166.83x
INTEREST COVERAGE RATIO AVG TTM
-306.77x
INTEREST COVERAGE RATIO AVG 3Y
-8.48x
INTEREST COVERAGE RATIO AVG 5Y
N/A
INTEREST COVERAGE RATIO AVG 10Y
N/A
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-280.36%
CURRENT VS 3Y AVG
-13666.68%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-5.79x
median of 488 covered companies
CURRENT VS SECTOR MEDIAN
-20052.56%
vs the sector median at left
Genelux Corporation
Market Cap
$115.46M
Interest Coverage Ratio
-1166.83x
TTM Avg
-306.77x
3Y Avg
-8.48x
5Y Avg
N/A
Market Cap
$114.48M
Interest Coverage Ratio
-2256.36x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$116.34M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$116.80M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.69M
Interest Coverage Ratio
-280.53x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.82M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$117.76M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.05M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Genelux Corporation (GNLX) | $115.46M | -1166.83x | -306.77x | -8.48x | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.48M | -2256.36x | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.34M | N/A | N/A | N/A | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.80M | N/A | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $112.69M | -280.53x | N/A | N/A | N/A |
| MaxCyte, Inc. (MXCT)vs › | $113.01M | N/A | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $112.82M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $117.76M | N/A | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $112.05M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $111.14M | N/A | 30.61x | 29.12x | 24.09x |
Interest Coverage
-1166.8x
Debt/Equity
0.15
Current Ratio
2.39
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2023-12-31 | -1166.83x |
| 2023-09-30 | -126.36x |
| 2023-06-30 | -224.79x |
| 2023-03-31 | -8.16x |
| 2022-12-31 | -7.72x |
| 2022-09-30 | 18.94x |
| 2022-06-30 | -8.36x |
| 2022-03-31 | -10.28x |
| 2021-12-31 | -9.87x |
| 2021-09-30 | -7.71x |
| 2021-06-30 | -7.86x |
| 2021-03-31 | -7.08x |
| 2020-12-31 | -9.25x |
| 2020-09-30 | -9.25x |
| 2020-06-30 | -9.25x |
| 2020-03-31 | -8.77x |
